Neuqip Tablet 0.25 Milligrams (Ropinirole Hydrochloride)

Adult dose

1. Individualized dose titration is recommended based on efficacy and tolerability. (1) Idiopathic Parkinson's disease It is preferable to take this medication 3 times daily with food to improve gastrointestinal tolerability. Initial therapy: Take 0.25mg 3 times daily. The treatment regimen for the first 4 weeks is as follows: Week (weeks) 1: Dose per administration (mg) 0.25, daily dose (mg) 0.75 Week (weeks) 2: Dose per administration (mg) 0.5, daily dose (mg) 1.5 Week (weeks) 3: Dose per administration (mg) 0.75, daily dose (mg) 2.25 Week (weeks) 4: Dose per administration (mg) 1.0, daily dose (mg) 3.0 Maintenance therapy: After initial therapy, the dose may be increased at weekly intervals up to 3mg per day. Therapeutic effects occur at daily doses of 3-9mg. If symptoms are not adequately controlled or symptom control is not maintained, the ropinirole dose may be increased until a clear therapeutic effect is achieved, but should not exceed 24mg per day. ① When administered as an adjunct to levodopa, the levodopa dose may be gradually reduced by approximately 20% of the total dose. ② When switching from another dopamine agonist to ropinirole, follow the manufacturer's guidelines for discontinuing the other medication before starting ropinirole. ③ As with other dopamine agonists, ropinirole should be discontinued gradually by reducing the number of daily doses over the course of 1 week. (2) Primary restless legs syndrome Ropinirole should be taken once daily before bedtime, 1~3 hours before bedtime. Initial therapy (week 1): The recommended initial dose is 0.25mg once daily for 2 days, taken 1~3 hours before bedtime. If this dose is well tolerated, it may be increased to 0.5mg once daily from day 3 through the last day of the first week of treatment (day 7). Maintenance therapy (from week 2): After initial therapy, the daily dose may be increased according to the following schedule until an optimal treatment response is achieved. Week (weeks) 2: Dose per administration (mg) 1 Week (weeks) 3: Dose per administration (mg) 1.5 Week (weeks) 4: Dose per administration (mg) 2 Week (weeks) 5: Dose per administration (mg) 2.5 Week (weeks) 6: Dose per administration (mg) 3 Week (weeks) 7: Dose per administration (mg) 4 The safety and efficacy of doses above 4mg/day have not been established in patients with restless legs syndrome. As with other dopamine agonists, treatment with this medication should be discontinued gradually while reducing the daily dose. If treatment with this medication has been interrupted for a significant period, it is recommended that treatment be restarted using the dose adjustment schedule above. 2. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 30-50mL /min), because ropinirole clearance is unchanged. Use of this medication has not been studied in patients with severe renal impairment (creatinine clearance ＜30mL/min); therefore, ropinirole is not recommended in these patients. 3. Patients with hepatic impairment: Use of this medication has not been studied in patients with hepatic impairment; therefore, ropinirole is not recommended in these patients. 4. Use in older adults: Ropinirole clearance is reduced in patients 65 years of age and older, but the dose for older patients may be adjusted in the usual manner according to the patient's clinical response.

Child dose

④ Use in children: Parkinson's disease does not occur in children. Therefore, no studies on the use of ropinirole in this population have been reported, and it should not be administered to children.

This medication should be used with caution in patients with severe heart or vascular problems. When taken with other blood pressure medications or heart rhythm control medications, hypotension, bradycardia, or arrhythmia may occur, so caution is advised. Patients with severe mental illnesses should only use this medication when the benefits outweigh the risks. Patients may suddenly fall asleep or experience abrupt sleep during the day while taking this medication, so it is advised to avoid dangerous activities such as driving or operating machinery. Women who are allergic to this medication, pregnant, or breastfeeding should not take it. Patients with specific genetic issues, such as lactose intolerance, should also not take this medication. Nausea, drowsiness, edema, abdominal pain, vomiting, dizziness, hallucinations, confusion, and other side effects may occur; if symptoms are severe, consult a physician. Especially, patients with Parkinson's disease should be cautious of side effects such as hypotension, heart rhythm abnormalities, and movement disorders. This medication should not be used during pregnancy as it may harm the fetus and should be avoided during breastfeeding as it can suppress milk secretion. Safety and efficacy have not been confirmed for children under 18 years of age, so it is not recommended for this age group. In case of overdose, symptoms such as nausea, dizziness, hallucinations, palpitations, drowsiness, and confusion may occur, and immediate contact with a medical institution is necessary. Store this medication in a dry, cool place out of the reach of children. It is advisable not to take this medication with other dopamine drugs, and dose adjustments may be necessary depending on specific medications or conditions. While taking this medication, regular monitoring is necessary as mental changes or impulse control disorders may occur.

Nausea, drowsiness, leg edema, abdominal pain, vomiting, syncope, dyskinesia, hallucinations, confusion, dizziness, sudden sleep, dyspepsia, constipation, orthostatic hypotension, hypotension, peripheral edema, agitation, delusions, paranoia, delirium, atypical psychiatric reactions, increased libido, pathological gambling, compulsive spending, binge eating, aggressiveness, hypersensitivity, hives, angioedema, rash, itching, fatigue, upper respiratory infection, arthralgia, injury, dry mouth, pain, diarrhea, myalgia, sensory abnormalities, increased sweating, cough, viral infection, migraine, rhinitis, sinusitis, insomnia, weakness, tremor, anxiety, confusion, fever, chest pain, muscle rigidity, frequent urination, dysgeusia, abnormal gait, illusion, dysuria, facial edema, peripheral ischemia, loss of appetite, dyspnea, weight loss, sleep disturbance, vasovagal syncope, visual hallucinations, hyperhidrosis, claustrophobia, chorea, palpitations, nightmares, movement disorders, impulse control disorder, appendicitis, intraluminal air in the gastrointestinal tract, urine discoloration, vesicles

Store this medication in a cool place below 25 degrees and keep it in a tightly sealed container to prevent light exposure. This will help maintain the medication's effectiveness and prevent degradation.

Appearance

White pentagonal film-coated tablets

Package unit

100 tablets (10 tablets/PTP packaging x 10)